Valuation: Genelux Corporation

Market Cap 109M 96.11M 90.53M 82.74M 155M 10.49B 156M 1.09B 421M 5.35B 411M 402M 17.37B P/E 2026 *
-2.98x
P/E 2027 * -3.11x
Enterprise Value 109M 96.11M 90.53M 82.74M 155M 10.49B 156M 1.09B 421M 5.35B 411M 402M 17.37B EV / Sales 2026 *
-
EV / Sales 2027 * 13.9x
Free-Float
86.3%
Yield 2026 *
-
Yield 2027 * -
1 day-3.38%
1 week+3.85%
Current month-7.07%
1 month-10.66%
3 months-16.78%
6 months-2.02%
Current year-44.27%
1 week 2.41
Extreme 2.41
2.64
1 month 2.31
Extreme 2.31
2.95
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
28.36
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 2014-05-27
Director of Finance/CFO 42 2025-01-29
Chief Tech/Sci/R&D Officer 52 2026-01-01
Director TitleAgeSince
Director/Board Member 68 2002-08-31
Chairman 73 2013-12-31
Chairman 67 2023-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Sell

Chief Technology Officer

-9,683 0.0214%
8/31/26 Sell

Chief Executive Officer

-34,463 0.0762%
8/31/26 Sell

Chief Technology Officer

-10,257 0.0227%
Change 5-day change 1-year change 3-year change Capi.($)
-3.38%+3.85%-44.01%-90.96% 113M
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-1.63%+33.14%+74.86% 59.55B
+2.71%-0.84%-16.39%+364.46% 25.84B
+0.81%+3.58%+1.01%-5.14% 24.73B
-1.05%+2.58%+24.27%-10.32% 20.87B
-1.70%-4.15%+147.82%+325.69% 15.32B
+2.15%+2.06%+45.57%+169.79% 14.06B
-0.43%-5.32%-14.46%+775.94% 13.12B
+0.04%-3.00%+15.76%+234.69% 11.85B
Average -0.43%+0.02%+24.77%+194.32% 25.96B
Weighted average by Cap. -0.71%-0.22%+34.89%+160.19%

Financials

2026 *2027 *
Net sales - 7.85M 6.9M 6.5M 5.94M 11.1M 753M 11.2M 77.89M 30.2M 384M 29.47M 28.83M 1.25B
Net income -36.96M -32.49M -30.6M -27.97M -52.28M -3.55B -52.74M -367M -142M -1.81B -139M -136M -5.87B -40.91M -35.96M -33.87M -30.96M -57.86M -3.93B -58.37M -406M -157M -2B -154M -150M -6.5B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
26-09-24 US$2.440 -2.98% 151,955
26-09-23 US$2.515 -3.64% 115,792
26-09-22 US$2.610 +1.95% 161,803
26-09-21 US$2.560 +1.19% 197,287
26-09-18 US$2.530 0.00% 143,118
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.515USD
Average target price
18.83USD
Spread / Average Target
+648.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock